SAN DIEGO, May 11, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing ...

Addressing obviousness issues, the U. S. Court of Appeals for the Federal Circuit affirmed the district court’s invalidity conclusion, agreeing that the elements present in the prior art—including ...

Prometheus Biosciences contends that the current treatments for inflammatory bowel disease are inadequate, taking a “one-size-fits-all approach” that doesn’t account for biologic variation. The ...

NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.

In Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc., [1] a recent decision involving methods of treating a specific subset of patients, the Court of Appeals for the Federal Circuit (“Federal ...

After four years working to turn around Bausch Health's Salix Pharmaceuticals, President Mark McKenna is leaving. McKenna will this week become the CEO of a new precision medicine drug developer, ...

The Supreme Court unanimously rejects Nestle's (OTCPK:NSRGY) Prometheus Labs request for two patents for a test that enables doctors to set drug dosages for patients with Crohn's disease. The justices ...

Today, Senator Thom Tillis (R-NC), the Ranking Member of the Senate IP Subcommittee, released the first draft of the Patent Eligibility Restoration Act of 2022, which if enacted would, at a minimum, ...